A
Allcyte
Enabling patient-centric R&D with in primary human tissues at single-cell resolution using imaging and AI
About Allcyte
Allcyte GmbH operates in the biotechnology sector, specializing in functional drug testing for cancer treatment. The company serves two primary client groups: physicians treating cancer patients and pharmaceutical companies developing new drugs. Allcyte's core technology, called pharmacoscopy, measures the action of drugs in viable primary human tissue samples at the single-cell level. This approach aims to predict clinical drug activity before human trials, offering a significant advantage over traditional genetic-driven precision medicine, which often lacks precise answers. The business model revolves around providing actionable insights that help physicians select the most effective drugs for their patients and assist pharmaceutical companies in identifying the most promising drug candidates for clinical development. Allcyte generates revenue through service fees charged to both healthcare providers and pharmaceutical firms for utilizing its platform. The company operates primarily in the oncology market, focusing on improving patient outcomes and increasing the success rates of clinical studies.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2017
- Headquarters
- Vienna, Austria
- Open positions
- None listed
- Dealroom signal
- 51.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Drug Development, Core AI, Precision Medicine, Spinout, Tech for Biotech and Pharma, AI Drug Discovery, Techbio
- Technology
- Artificial Intelligence, Deep Tech
- Client focus
- b2b
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Jun 2021 | $55M | $55M | Exscientia | — |
| SEED✓Equity / VC | Mar 2021 | $6M | $24M | 42CAP · Push Ventures · Air Street Capital · VP Venture Partners | — |
Growth signals
Latest recorded traffic for Allcyte is 510 monthly website visits, down 90.4% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed7 investors entered at this stage
- VAVenture Partners AG
PUSH
Air Street Capital
42CAP
Push Ventures
VP Venture Partners
Amino Collective
Other known investors4 additional known investors
Austrian Academy of Sciences
CeMM
Exscientia
MK Venture Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Allcyte on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Allcyte’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.